Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

Core Insights - Nexalin Technology, Inc. has demonstrated through three independent studies that its non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology can improve cognitive function and brain activity in Alzheimer's disease patients [1][2][7] Study Summaries - TRANSFORM-AD Study: A randomized, double-blind trial involving 46 patients showed that 30 one-hour DIFS sessions over 15 days led to immediate improvements in cognitive scores (MMSE and MoCA) and brain activity, marking the first evidence of hippocampal activation from DIFS in Alzheimer's [3] - Altered Neuronal Activity Study: This study utilized resting-state fMRI to reveal significant increases in functional amplitude of low-frequency fluctuations (fALFF) and regional homogeneity (ReHo) in critical brain areas, indicating DIFS' effectiveness in restoring neuronal synchronization and blood flow [4] - Modulation of Connectivity Study: Published in Radiology, this research found that DIFS significantly enhanced cognitive function and connectivity between the hippocampus and cortical regions, with improvements correlating with imaging findings, thus linking brain network modulation to cognitive outcomes [5] Market Context - The global Alzheimer's market is projected to exceed $20 billion annually, with current treatments primarily focused on pharmacologic therapies targeting amyloid or tau proteins, which often provide modest benefits and carry safety risks [6] - Nexalin's DIFS technology offers a fundamentally different approach, potentially positioning the company as a paradigm-shifting solution for patients seeking safe and effective alternatives to traditional drug regimens at lower costs [6][8] Company Statements - The convergence of findings from the three studies supports the efficacy of Nexalin's DIFS technology in restoring brain networks and improving cognitive function in Alzheimer's patients, representing a compelling non-invasive data set in the field [7] - The company emphasizes that its DIFS technology is drug-free, non-invasive, and has no reported serious side effects, targeting network dysfunction rather than protein accumulation [8]